Schematic overview of the cellular and molecular mechanisms involved in the cancer progression, including the proposed cellular and molecular mechanisms in cancer cells trajectory. AT1: alveolar type 1 cells; AT2: alveolar type 2 cells; AAH: atypical adenomatous hyperplasia; AIS: adenocarcinoma in situ; MIA: minimally invasive adenocarcinoma; IA: invasive adenocarcinoma; EMT: epithelial-mesenchymal transition

Home

Download

Statistics

Help

Contact

	Gene summary
	Malignant transformation analysis
	Malignant transformation related pathway analysis
	Cell-cell communication analysis
	Single-cell gene regulatory network inference analysis
	Somatic mutation of malignant transformation related genes
	Related drugs of malignant transformation related genes

Gene: SHMT1

Gene summary for SHMT1

Gene summary.

Gene information	Species	Human
	Gene symbol	SHMT1
	Gene ID	6470
	Gene name	serine hydroxymethyltransferase 1
	Gene Alias	CSHMT
	Cytomap	17p11.2
	Gene Type	protein-coding
	GO ID	GO:0006082
	UniProtAcc	P34896

Top

Malignant transformation analysis

Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells

Malignant transformation involving gene list.

Entrez ID	Symbol	Replicates	Species	Organ	Tissue	Adj P-value	Log2FC	Malignancy
6470	SHMT1	LZE4T	Human	Esophagus	ESCC	1.54e-05	2.41e-02	0.0811
6470	SHMT1	LZE22D1	Human	Esophagus	HGIN	1.29e-02	5.07e-02	0.0595
6470	SHMT1	LZE24T	Human	Esophagus	ESCC	8.21e-16	2.64e-01	0.0596
6470	SHMT1	LZE6T	Human	Esophagus	ESCC	7.45e-07	1.13e-01	0.0845
6470	SHMT1	P2T-E	Human	Esophagus	ESCC	2.14e-17	4.56e-01	0.1177
6470	SHMT1	P4T-E	Human	Esophagus	ESCC	8.69e-20	5.32e-01	0.1323
6470	SHMT1	P5T-E	Human	Esophagus	ESCC	1.16e-10	3.34e-03	0.1327
6470	SHMT1	P8T-E	Human	Esophagus	ESCC	5.18e-29	6.69e-01	0.0889
6470	SHMT1	P9T-E	Human	Esophagus	ESCC	4.21e-03	6.55e-02	0.1131
6470	SHMT1	P10T-E	Human	Esophagus	ESCC	1.50e-08	2.35e-01	0.116
6470	SHMT1	P11T-E	Human	Esophagus	ESCC	6.64e-04	3.58e-01	0.1426
6470	SHMT1	P12T-E	Human	Esophagus	ESCC	4.97e-25	3.02e-01	0.1122
6470	SHMT1	P15T-E	Human	Esophagus	ESCC	1.80e-04	1.78e-01	0.1149
6470	SHMT1	P16T-E	Human	Esophagus	ESCC	4.66e-32	7.05e-01	0.1153
6470	SHMT1	P19T-E	Human	Esophagus	ESCC	5.76e-03	4.55e-01	0.1662
6470	SHMT1	P20T-E	Human	Esophagus	ESCC	3.44e-11	2.11e-01	0.1124
6470	SHMT1	P21T-E	Human	Esophagus	ESCC	1.11e-28	6.52e-01	0.1617
6470	SHMT1	P22T-E	Human	Esophagus	ESCC	1.86e-11	2.10e-01	0.1236
6470	SHMT1	P23T-E	Human	Esophagus	ESCC	9.66e-03	1.75e-01	0.108
6470	SHMT1	P24T-E	Human	Esophagus	ESCC	1.79e-09	1.46e-01	0.1287

Page: 1 2 3 4 5

Transcriptomic changes along malignancy continuum.

Tissue	Expression Dynamics	Abbreviation
Esophagus		ESCC: Esophageal squamous cell carcinoma
		HGIN: High-grade intraepithelial neoplasias
		LGIN: Low-grade intraepithelial neoplasias
Liver		HCC: Hepatocellular carcinoma
		NAFLD: Non-alcoholic fatty liver disease
Oral Cavity		EOLP: Erosive Oral lichen planus
		LP: leukoplakia
		NEOLP: Non-erosive oral lichen planus
		OSCC: Oral squamous cell carcinoma
Skin		AK: Actinic keratosis
		cSCC: Cutaneous squamous cell carcinoma
		SCCIS:squamous cell carcinoma in situ
Thyroid		ATC: Anaplastic thyroid cancer
		HT: Hashimoto's thyroiditis
		PTC: Papillary thyroid cancer

∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.

Top

Malignant transformation related pathway analysis

Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer

Figure of enriched GO biological processes.

Tissue	Disease Stage	Enriched GO biological Processes
Colorectum	AD
Colorectum	SER
Colorectum	MSS
Colorectum	MSI-H
Colorectum	FAP

∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).

Page: 1 2 3 4 5 6 7 8 9

Enriched GO biological processes.

GO ID	Tissue	Disease Stage	Description	Gene Ratio	Bg Ratio	pvalue	p.adjust	Count
GO:00359991	Liver	HCC	tetrahydrofolate interconversion	10/7958	10/18723	1.92e-04	1.49e-03	10
GO:0006767	Liver	HCC	water-soluble vitamin metabolic process	39/7958	59/18723	2.14e-04	1.63e-03	39
GO:003424921	Liver	HCC	negative regulation of cellular amide metabolic process	144/7958	273/18723	3.80e-04	2.61e-03	144
GO:19016062	Liver	HCC	alpha-amino acid catabolic process	53/7958	87/18723	4.01e-04	2.71e-03	53
GO:0042440	Liver	HCC	pigment metabolic process	51/7958	84/18723	5.74e-04	3.65e-03	51
GO:001714821	Liver	HCC	negative regulation of translation	129/7958	245/18723	8.14e-04	4.87e-03	129
GO:0046655	Liver	HCC	folic acid metabolic process	12/7958	14/18723	1.17e-03	6.54e-03	12
GO:00466531	Liver	HCC	tetrahydrofolate metabolic process	15/7958	19/18723	1.36e-03	7.28e-03	15
GO:00091131	Liver	HCC	purine nucleobase biosynthetic process	9/7958	10/18723	2.79e-03	1.31e-02	9
GO:0051262	Liver	HCC	protein tetramerization	50/7958	87/18723	3.42e-03	1.55e-02	50
GO:0046148	Liver	HCC	pigment biosynthetic process	37/7958	62/18723	4.73e-03	2.02e-02	37
GO:00061441	Liver	HCC	purine nucleobase metabolic process	14/7958	19/18723	5.94e-03	2.44e-02	14
GO:0006766	Liver	HCC	vitamin metabolic process	57/7958	106/18723	1.25e-02	4.53e-02	57
GO:0051289	Liver	HCC	protein homotetramerization	33/7958	57/18723	1.37e-02	4.86e-02	33
GO:000641720	Oral cavity	OSCC	regulation of translation	274/7305	468/18723	4.39e-18	4.63e-16	274
GO:19908237	Oral cavity	OSCC	response to leukemia inhibitory factor	58/7305	95/18723	1.10e-05	1.14e-04	58
GO:19908307	Oral cavity	OSCC	cellular response to leukemia inhibitory factor	57/7305	94/18723	1.75e-05	1.71e-04	57
GO:00091132	Oral cavity	OSCC	purine nucleobase biosynthetic process	10/7305	10/18723	8.14e-05	6.26e-04	10
GO:0051259	Oral cavity	OSCC	protein complex oligomerization	121/7305	238/18723	1.29e-04	9.21e-04	121
GO:007252120	Oral cavity	OSCC	purine-containing compound metabolic process	199/7305	416/18723	1.34e-04	9.53e-04	199

Page: 1 2 3 4 5 6 7 8 9

Enriched KEGG pathways.

Pathway ID	Tissue	Disease Stage	Description	Gene Ratio	Bg Ratio	pvalue	p.adjust	qvalue	Count
hsa0120016	Esophagus	HGIN	Carbon metabolism	31/1383	115/8465	2.51e-03	2.10e-02	1.67e-02	31
hsa012306	Esophagus	HGIN	Biosynthesis of amino acids	21/1383	75/8465	7.38e-03	4.63e-02	3.68e-02	21
hsa0120017	Esophagus	HGIN	Carbon metabolism	31/1383	115/8465	2.51e-03	2.10e-02	1.67e-02	31
hsa0123013	Esophagus	HGIN	Biosynthesis of amino acids	21/1383	75/8465	7.38e-03	4.63e-02	3.68e-02	21
hsa0120023	Esophagus	ESCC	Carbon metabolism	79/4205	115/8465	2.50e-05	1.21e-04	6.22e-05	79
hsa012405	Esophagus	ESCC	Biosynthesis of cofactors	97/4205	153/8465	3.88e-04	1.35e-03	6.94e-04	97
hsa0123023	Esophagus	ESCC	Biosynthesis of amino acids	49/4205	75/8465	4.35e-03	1.12e-02	5.74e-03	49
hsa015232	Esophagus	ESCC	Antifolate resistance	22/4205	30/8465	7.23e-03	1.76e-02	8.99e-03	22
hsa006306	Esophagus	ESCC	Glyoxylate and dicarboxylate metabolism	21/4205	30/8465	1.95e-02	4.35e-02	2.23e-02	21
hsa0120033	Esophagus	ESCC	Carbon metabolism	79/4205	115/8465	2.50e-05	1.21e-04	6.22e-05	79
hsa0124012	Esophagus	ESCC	Biosynthesis of cofactors	97/4205	153/8465	3.88e-04	1.35e-03	6.94e-04	97
hsa0123033	Esophagus	ESCC	Biosynthesis of amino acids	49/4205	75/8465	4.35e-03	1.12e-02	5.74e-03	49
hsa0152311	Esophagus	ESCC	Antifolate resistance	22/4205	30/8465	7.23e-03	1.76e-02	8.99e-03	22
hsa0063013	Esophagus	ESCC	Glyoxylate and dicarboxylate metabolism	21/4205	30/8465	1.95e-02	4.35e-02	2.23e-02	21
hsa0120010	Liver	NAFLD	Carbon metabolism	26/1043	115/8465	1.39e-03	1.71e-02	1.38e-02	26
hsa0120011	Liver	NAFLD	Carbon metabolism	26/1043	115/8465	1.39e-03	1.71e-02	1.38e-02	26
hsa0120021	Liver	Cirrhotic	Carbon metabolism	64/2530	115/8465	6.37e-09	1.18e-07	7.26e-08	64
hsa006304	Liver	Cirrhotic	Glyoxylate and dicarboxylate metabolism	20/2530	30/8465	3.36e-05	2.54e-04	1.57e-04	20
hsa01240	Liver	Cirrhotic	Biosynthesis of cofactors	66/2530	153/8465	3.11e-04	1.99e-03	1.23e-03	66
hsa00260	Liver	Cirrhotic	Glycine, serine and threonine metabolism	22/2530	40/8465	7.85e-04	4.51e-03	2.78e-03	22

Page: 1 2 3

Top

Cell-cell communication analysis

Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states

Ligand

Receptor

LRpair

Pathway

Tissue

Disease Stage

Page: 1

Top

Single-cell gene regulatory network inference analysis

Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states

Cell Type

Tissue

Disease Stage

Target Gene

RSS

Regulon Activity

∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.

Page: 1

Top

Somatic mutation of malignant transformation related genes

Annotation of somatic variants for genes involved in malignant transformation

Hugo Symbol

Variant Class

Variant Classification

dbSNP RS

HGVSc

HGVSp

HGVSp Short

SWISSPROT

BIOTYPE

SIFT

PolyPhen

Tumor Sample Barcode

Tissue

Histology

Sex

Age

Stage

Therapy Types

Drugs

Outcome

SHMT1

SNV

Missense_Mutation

novel

c.800T>A

p.Ile267Asn

p.I267N

P34896

protein_coding

deleterious(0)

probably_damaging(0.999)

TCGA-A2-A0CT-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Chemotherapy

cytoxan

SHMT1

SNV

Missense_Mutation

novel

c.998N>A

p.Ala333Asp

p.A333D

P34896

protein_coding

tolerated(0.17)

possibly_damaging(0.624)

TCGA-AO-A12A-01

Breast

breast invasive carcinoma

Female

<65

I/II

Chemotherapy

cyclophosphamide

SHMT1

SNV

Missense_Mutation

novel

c.426N>A

p.Asp142Glu

p.D142E

P34896

protein_coding

deleterious(0)

probably_damaging(0.964)

TCGA-EW-A2FR-01

Breast

breast invasive carcinoma

Female

<65

III/IV

Chemotherapy

epirubicin

SHMT1

insertion

Nonsense_Mutation

novel

c.217_218insG

p.Tyr73Ter

p.Y73*

P34896

protein_coding

TCGA-AO-A0JB-01

Breast

breast invasive carcinoma

Female

<65

III/IV

Chemotherapy

cyclophosphamide

SHMT1

insertion

In_Frame_Ins

novel

c.216_217insAGGTCAGTGTCATCTGAGGGATGCTGCAGAAGG

p.Lys72_Tyr73insArgSerValSerSerGluGlyCysCysArgArg

p.K72_Y73insRSVSSEGCCRR

P34896

protein_coding

TCGA-AO-A0JB-01

Breast

breast invasive carcinoma

Female

<65

III/IV

Chemotherapy

cyclophosphamide

SHMT1

insertion

Nonsense_Mutation

novel

c.501_502insATTATAAAATAAGGTTTGTGTTTGACTATCTTGCCCAGTGGAG

p.Glu168IlefsTer4

p.E168Ifs*4

P34896

protein_coding

TCGA-BH-A0HX-01

Breast

breast invasive carcinoma

Female

<65

I/II

Chemotherapy

adrimycin

SHMT1

SNV

Missense_Mutation

rs778033192

c.1186N>G

p.Leu396Val

p.L396V

P34896

protein_coding

deleterious(0.02)

benign(0.289)

TCGA-DR-A0ZM-01

Cervix

cervical & endocervical cancer

Female

<65

III/IV

Unspecific

Cisplatin

SHMT1

SNV

Missense_Mutation

novel

c.1449N>G

p.Phe483Leu

p.F483L

P34896

protein_coding

tolerated_low_confidence(0.76)

benign(0)

TCGA-Q1-A73O-01

Cervix

cervical & endocervical cancer

Female

<65

I/II

Chemotherapy

cisplatin

SHMT1

SNV

Missense_Mutation

c.695N>C

p.Ile232Thr

p.I232T

P34896

protein_coding

deleterious(0.02)

possibly_damaging(0.884)

TCGA-AA-A01P-01

Colorectum

colon adenocarcinoma

Female

>=65

III/IV

Unknown

SHMT1

SNV

Missense_Mutation

c.137N>C

p.Val46Ala

p.V46A

P34896

protein_coding

tolerated(0.29)

benign(0.014)

TCGA-AZ-6598-01

Colorectum

colon adenocarcinoma

Female

>=65

I/II

Unknown

Page: 1 2 3 4 5

Top

Related drugs of malignant transformation related genes

Identification of chemicals and drugs interact with genes involved in malignant transfromation

(DGIdb 4.0)

Entrez ID	Symbol	Category	Interaction Types	Drug Claim Name	Drug Name	PMIDs
6470	SHMT1	ENZYME		fluorouracil	FLUOROURACIL	22044939
6470	SHMT1	ENZYME		leucovorin	LEUCOVORIN	22044939
6470	SHMT1	ENZYME		methotrexate	METHOTREXATE	20386493,18322994,15797993,22838948,18368069
6470	SHMT1	ENZYME		bevacizumab	BEVACIZUMAB	22044939
6470	SHMT1	ENZYME		irinotecan	IRINOTECAN	22044939

Page: 1